Aurinia Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Aurinia Pharmaceuticals

03/08/2023 14:34

* Aurinia Pharmaceuticals Inc  AUPH.OQ  reported a quarterly
adjusted loss of 8 cents​​ per share for the quarter ended in
June. The mean expectation of seven analysts for the quarter was
for a loss of 18 cents per share.
    * Revenue rose 47.2% to $41.49 million from a year ago;
analysts
expected $38.15 million. 
    * Aurinia Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 8 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aurinia Pharmaceuticals Inc shares had risen by 4.6% this
quarter and gained 134.5% so far this year.
    * The company reported a quarterly loss of $11.49 million.
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 01:34 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.18          -0.08          Beat
 Mar. 31 2023      -0.22          -0.18          Beat
 Dec. 31 2022      -0.27          -0.18          Beat
 Sep. 30 2022      -0.17          -0.06          Beat